Overview

Arginine Therapy for Sickle Cell Disease Pain

Status:
Completed
Trial end date:
2021-02-21
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine whether giving extra arginine, a simple amino acid, to patients with sickle cell disease seeking treatment for a pain crisis (vaso-occlusive painful events (VOE) will decrease pain scores, decrease the need for pain medications or decrease length of hospital stay or emergency department visit. Funding Source - FDA OOPD.
Phase:
Phase 2
Details
Lead Sponsor:
Emory University
Collaborators:
Children's Healthcare of Atlanta
National Center for Complementary and Integrative Health (NCCIH)